First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

E-resources

PDF

Peer reviewed Open access

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

Shaw, Alice T; Bauer, Todd M; de Marinis, Filippo; Felip, Enriqueta; Goto, Yasushi; Liu, Geoffrey; Mazieres, Julien; Kim, Dong-Wan; Mok, Tony; Polli, Anna; Thurm, Holger; Calella, Anna M; Peltz, Gerson; Solomon, Benjamin J

New England journal of medicine/The New England journal of medicine, 11/2020, Volume: 383, Issue: 21

Journal Article

In an interim analysis of a trial involving 296 patients with ALK -positive non–small-cell lung cancer, lorlatinib, an anaplastic lymphoma kinase inhibitor, was superior to crizotinib in response (in 76% vs. 58%), 12-month progression-free survival (78% vs. 39%), and intracranial disease response (82% vs. 23%). Altered lipid levels were the major toxic effect associated with lorlatinib.

Keep searching

Author

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme